$10.69
0.151.42%
Pre-Market: 8:11 AM EDT
15 minutes delayed
Comments
Loading...
ARS Pharmaceuticals
SPRYNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ARS Pharmaceuticals (NASDAQ:SPRY) Stock, Analyst Ratings, Price Targets, Forecasts
ARS Pharmaceuticals Inc has a consensus price target of $17 based on the ratings of 4 analysts. The high is $19 issued by Wedbush on March 11, 2024. The low is $14 issued by SVB Leerink on December 13, 2022. The 3 most-recent analyst ratings were released by Wedbush, Leerink Partners, and Wedbush on March 11, 2024, March 5, 2024, and November 13, 2023, respectively. With an average price target of $16.67 between Wedbush, Leerink Partners, and Wedbush, there's an implied 55.91% upside for ARS Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Leerink Partners
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for ARS Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/11/2024 | Buy Now | 77.74% | Wedbush | Andreas Argyrides | → $19 | Reiterates | Outperform → Outperform | Get Alert |
| 03/05/2024 | Buy Now | 68.38% | Leerink Partners | Roanna Ruiz | $6 → $18 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/13/2023 | Buy Now | 21.61% | Wedbush | Andreas Argyrides | $5 → $13 | Maintains | Outperform | Get Alert |
| 09/21/2023 | Buy Now | -53.23% | Wedbush | Andreas Argyrides | $15 → $5 | Maintains | Outperform | Get Alert |
| 09/20/2023 | Buy Now | — | William Blair | Tim Lugo | — | Downgrade | Outperform → Market Perform | Get Alert |
| 08/14/2023 | Buy Now | 40.32% | Wedbush | Andreas Argyrides | → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 06/21/2023 | Buy Now | 40.32% | Wedbush | Andreas Argyrides | $17 → $15 | Maintains | Outperform | Get Alert |
| 05/18/2023 | Buy Now | 59.03% | Wedbush | Andreas Argyrides | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 59.03% | Wedbush | Andreas Argyrides | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2023 | Buy Now | 59.03% | Wedbush | Andreas Argyrides | → $17 | Reiterates | → Outperform | Get Alert |
| 01/31/2023 | Buy Now | -6.45% | Wedbush | Andreas Argyrides | → $10 | Initiates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | — | William Blair | Tim Lugo | — | Initiates | → Outperform | Get Alert |
| 12/13/2022 | Buy Now | 30.96% | SVB Leerink | Roanna Ruiz | → $14 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for ARS Pharmaceuticals (SPRY) stock?
The latest price target for ARS Pharmaceuticals (NASDAQ:SPRY) was reported by Wedbush on March 11, 2024. The analyst firm set a price target for $19.00 expecting SPRY to rise to within 12 months (a possible 77.74% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ARS Pharmaceuticals (SPRY)?
The latest analyst rating for ARS Pharmaceuticals (NASDAQ:SPRY) was provided by Wedbush, and ARS Pharmaceuticals reiterated their outperform rating.
When was the last upgrade for ARS Pharmaceuticals (SPRY)?
The last upgrade for ARS Pharmaceuticals Inc happened on March 5, 2024 when Leerink Partners raised their price target to $18. Leerink Partners previously had a market perform for ARS Pharmaceuticals Inc.
When was the last downgrade for ARS Pharmaceuticals (SPRY)?
The last downgrade for ARS Pharmaceuticals Inc happened on September 20, 2023 when William Blair changed their price target from N/A to N/A for ARS Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ARS Pharmaceuticals (SPRY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on March 11, 2024 so you should expect the next rating to be made available sometime around March 11, 2025.
Is the Analyst Rating ARS Pharmaceuticals (SPRY) correct?
While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a reiterated with a price target of $0.00 to $19.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $10.69, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.